Loading
Track how much of each cancer drug patients actually receive and how often they need to reduce it, and use that to change the official dose when the label is too high.
Oncology drugs are often labelled at doses most patients cannot tolerate; dose reductions in practice are common but invisible to regulators. Project Optimus addresses dose selection before approval; nothing systematic addresses it after. The proposal uses structured prescribing data to publish real-world dose intensity, reduction rates and toxicity per drug annually, with a regulatory pathway to update labels when the real-world modal dose differs from the label.
Shares Real-world evidence, Weak real-world evidence and registries, Toxicity and quality of life are undervalued.
Shares Real-world evidence, Weak real-world evidence and registries, Toxicity and quality of life are undervalued.
Shares Real-world evidence, Weak real-world evidence and registries.
Shares Real-world evidence, Weak real-world evidence and registries.
Shares Real-world evidence, Weak real-world evidence and registries.
Shares Real-world evidence, Weak real-world evidence and registries.
Shares Real-world evidence, Weak real-world evidence and registries.
Shares Real-world evidence, Weak real-world evidence and registries.